Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins: Infectious diseases

• Published in: Clinical microbiology and infection Vol. 21; no. 2; pp. 179.e1 - 179.e7
• Main Authors: de Oliveira, MS, de Assis, DB, Freire, M P, Boas do Prado, GV, Machado, A S, Abdala, E, Pierrotti, L C, Mangini, C, Campos, L, Caiaffa Filho, HH, Levin, A S
• Format: Journal Article
• Language: English
• Published: 01-02-2015
• Subjects: Enterobacteriaceae; Klebsiella pneumoniae
• ISSN: 1198-743X
• DOI: 10.1016/j.cmi.2014.07.010

Treatment of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae infections (KPC-EI) remains a challenge. Combined therapy has been proposed as the best choice, but there are no clear data showing which combination therapy is superior. Our aim was to evaluate the effectiveness of antimicrobial regimens for treating KPC-EI. This was a retrospective cohort study of KPC-EI nosocomial infections (based on CDC criteria) between October 2009 and June 2013 at three tertiary Brazilian hospitals. The primary outcomes were the 30-day mortality for all infections and the 30-day mortality for patients with bacteraemia. Risk factors for mortality were evaluated by comparing clinical variables of survivors and nonsurvivors. In this study, 118 patients were included, of whom 78 had bacteraemia. Catheter-related bloodstream infections were the most frequent (43%), followed by urinary tract infections (n = 27, 23%). Monotherapy was used in 57 patients and combined treatment in 61 patients. The most common therapeutic combination was polymyxin plus carbapenem 20 (33%). Multivariate analysis for all infections (n = 118) and for bacteremic infections (n = 78) revealed that renal failure at the end of treatment, use of polymyxin and older age were prognostic factors for mortality. In conclusion, polymyxins showed suboptimal efficacy and combination therapy was not superior to monotherapy.